Quick start
A short orientation to what is known, what remains uncertain, what is medically risky, and what cultural material is protected.
Iboga is a Central African plant with living cultural histories. Ibogaine is an alkaloid studied for substance-use and neuropsychiatric questions. Howard Lotsof's 1962 report helped launch modern Western addiction-treatment interest in Ibogaine. Ibogaine is not FDA-approved as a treatment in the United States.
Long-term outcomes, relapse rates, denominators, confounders, selection bias, optimal research settings, and real-world safety rates remain difficult to interpret across clinics, countries, and study designs.
Cardiac risk, QT/QTc, bradycardia, rhythm events, electrolytes, medication interactions, psychiatric exclusions, polysubstance exposure, and emergency readiness shape the safety conversation.
Public history, conservation, terminology, and published interviews can be discussed. Initiation instructions, lineage-held ceremonial songs or chants, private ritual sequences, sacred designs, dosing instructions, and claims about Bwiti authority stay with authorized holders.
Two stories matter early: Howard Lotsof's 1962 report that Ibogaine unexpectedly interrupted heroin withdrawal and craving, and Hunter S. Thompson's 1972 Ed Muskie Ibogaine rumor, which belongs to political-media history rather than clinical evidence. IbogaBase separates foundational stories, rumor, advocacy, patents, and clinical data so readers can see what each source can and cannot prove.